ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1561

Development of Posterior Uveitis in Behçet’s Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement

Didar Ucar1, Basak Ecem Bircan2, Nigar Rustamli3, Bilge Batu Oto1, Vedat Hamuryudan4, Sinem Nihal Esatoglu5 and gulen Hatemi5, 1Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Ophthalmology, Istanbul, Turkey, 2Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, 3Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Internal Medicine, Istanbul, Turkey, 4Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 5Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

Meeting: ACR Convergence 2022

Keywords: Behçet's Syndrome, Eye Disorders, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: A considerable number of patients with Behçet’s syndrome (BS) have vitreous cells on slit lamp examination at the time of diagnosis. However, the prognostic importance of vitreous cells (VC) and their association with the development of posterior uveitis (PU) requiring immunosuppressive treatment is unknown.

Methods: The charts of 144 consecutive BS patients fulfilling ISG criteria who were registered between 2010 and 2011 were reviewed. At baseline visit 59/144 patients had VC in one eye or both eyes. Among the remaining patients, 66 patients had bilateral pan or posterior uveitis, 3 had no eye involvement, and 9 had insufficient data in their medical records. Among the 59 patients with VC, 42 patients with a follow-up of ≥2 years were included in this study.

Results: At baseline, among the 42 included patients (23 men, mean±SD age: 30.3±8.7 years), 22 had VC in both eyes, 10 had VC in only one eye, and 10 had VC in one eye and PU in the other eye. There was anterior uveitis (AU) in addition to VC in the same eye in 7 patients at baseline.

New PU developed in 13 patients during a mean follow-up of 1.8±1.2 years.

4 patients that developed PU in the eye with VC had had PU in the contralateral eye at baseline. This means 4 of 10 patients with VC in one eye and PU in the contralateral eye developed bilateral PU despite treatment. Additionally, 4 patients that developed PU in the eye with VC had anterior uveitis in the same eye at baseline.

Conclusion: Careful follow-up is required for patients with VC since almost one third developed PU within 2 years. The presence of PU in the contralateral eye and AU in the same eye may be risk factors for the development of PU in patients with VC.


Disclosures: D. Ucar, None; B. Bircan, None; N. Rustamli, None; B. Batu Oto, None; V. Hamuryudan, Celgene, AbbVie/Abbott, Novartis, UCB; S. Esatoglu, None; g. Hatemi, Celgene, UCB, Novartis, AbbVie/Abbott.

To cite this abstract in AMA style:

Ucar D, Bircan B, Rustamli N, Batu Oto B, Hamuryudan V, Esatoglu S, Hatemi g. Development of Posterior Uveitis in Behçet’s Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/development-of-posterior-uveitis-in-behcets-syndrome-patients-with-vitreous-cells-without-any-other-posterior-involvement/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-posterior-uveitis-in-behcets-syndrome-patients-with-vitreous-cells-without-any-other-posterior-involvement/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology